COMMENTARY

• April-Sept. Earnings Signal Watershed in Japan’s Shift to Generics
  December 15, 2014

• Wonder Drug? Savior? Avigan Clinical Trial for Ebola May Not Provide Clear-Cut Answer
  December 5, 2014

• Torii Eager to Carve Out New Market with Japan’s 1st Sublingual Allergen Immunotherapy
  November 25, 2014

• Was Weak Yen a Plus for April-Sept. Earnings? Profits Partly Canceled Out by Higher R&D, Import Costs
  November 18, 2014

• JPWA’s Uniform Tax Representation Will Benefit Wholesalers and Customers Alike
  November 10, 2014

• Can a More-Open ICH Maintain “Tri-Polar” Leadership? - Key Focus at Lisbon Meeting
  November 5, 2014

• Ex-Health Minister Tamura’s Clout Likely to Grow in Nagatacho
  October 14, 2014

• MHLW Has Trick Up Its Sleeve to Skirt 3 Straight Years of “Full-Scale” NHI Price Revisions
  October 6, 2014

• Revised PAL to Embrace “Deeper” Safety Measures, Yet Also Escape Clauses to Ease Company Burdens
  September 29, 2014

• Series of CRPC Drugs Make Japan Debut, Expanded Indications Key to Success
  September 24, 2014

• Picture of Future Regulations on Investigator-Led Clinical Research Emerging
  September 9, 2014

• With No Pilot at Helm, Pharma Industry Embroiled in Confusion with Voluntary Funding Disclosures
  September 1, 2014

• Wholesalers’ Q1 Earnings Remain Positive, Medical Fee Cut Rule Seen to Boost Accuracy of Financial Results in Sept.
  August 25, 2014

• Japanese Drug Makers Working to Increase Pace of Drug Discovery by Optimizing Operations at Research Centers
  August 18, 2014

• PMDA Sets Target Review Times for Partial Changes to Generic Approval - A New Way to Underpin Stable Supply
  August 4, 2014

• Competition Fuels Personalized Medicine Market, First-Line Positions Eyed for Xalkori, Alecensa
  July 28, 2014

• Can New Fast-Track Review System Perk Up Drug Makers’ Development Drive in Japan?
  July 7, 2014

• June Reimbursement Listing Could Mark Watershed in Japan Generic Market
  July 1, 2014

• Two Reasons MHLW Opposes Yearly NHI Price Revisions, “Annual” Dropped from Gov’t Policy Guidelines
  June 17, 2014

• Delicate Balancing Act Required for SGLT-2 Inhibitor Promotions - Safety vs Efficacy
  June 16, 2014

ページ